BUSINESS
Takeda Initiates Overseas PIII Trial of Actos for Delaying the Onset of MCI Due to Alzheimer’s Disease
Takeda Pharmaceutical announced on August 27 that it has initiated TOMMORROW, a global PIII clinical trial that will investigate the efficacy of its diabetes treatment Actos (pioglitazone) at delaying the onset of Alzheimer’s disease (AD). The trial is being conducted…
To read the full story
Related Article
- Takeda Fails in Key Actos Trial for Alzheimer’s
January 26, 2018
BUSINESS
- Daiichi Sankyo Targets Cancer Cure with IO-ADC Combo Strategy
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Servier Japan Seeks First-Line Pancreatic Cancer Use for Onivyde
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





